4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases
4SC AG announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with LEO Pharma A/S, Ballerup, Denmark with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.
The collaboration has the potential to result in a novel and convenient breakthrough therapy for chronic skin conditions. The innovative compound, currently in the early development state, has already been proven in preclinical models to significantly reduce if not entirely eradicate symptoms of psoriasis.
Under the agreement, LEO Pharma will issue an upfront payment of EUR 1 million to 4SC Discovery and additional funding for research and development. LEO Pharma will receive an exclusive option to license the worldwide marketing and commercialisation rights of the compound for use in inflammatory skin diseases, including psoriasis and other therapeutic areas. Upon LEO Pharma exercising the option, 4SC Discovery will be eligible for a milestone payment of up to EUR 3 million and further payments upon achieving specific development milestones of up to EUR 92 million as well as up to double-digit royalties.
Other news from the department business & finance
